Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

European markets closed lower on Wednesday, with traders monitoring corporate earnings and awaiting the Federal Reserve’s ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

Q1 2025 for the BANK of Greenland With a profit before tax of DKK 39.1 million for Q1, the BANK of Greenland made a sound start to 2025. As expected, the result is affected by the declining level of ...

As a licensed VASP under VARA’s globally recognized framework, DKK Digital is now authorized to offer a comprehensive suite ...

Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...

Interim Management Statement covering Q3 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2025- 31 March ...

Nini Pryds, Henning Friis Poulsen, Irini Angelidaki, and Leif Oxenløwe each received a prestigious Villum Investigator grant, ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...